Managing community-acquired pneumonia: Factors to consider in outpatient care

Postgraduate Medicine

Volumn 105, Issue 4, 1999, Pages 106-114

  Farber, Mark O ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GREPAFLOXACIN; LEVOFLOXACIN; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CONFERENCE PAPER; DRUG COST; DRUG EFFICACY; GRAM POSITIVE BACTERIUM; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MORTALITY; PATIENT COMPLIANCE; PNEUMONIA; PRACTICE GUIDELINE; RISK FACTOR; SEROLOGY; TREATMENT PLANNING;

EID: 0033043873     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1999.04.668     Document Type: Conference Paper

References (51)

1. Meeker DP, Longworth DL. Community-acquired pneumonia: an update. Cleve Clin J Med 1996;63(1):16-30
2. Finch RG, Woodhead MA. Practical considerations and guidelines for the management of community-acquired pneumonia. Drugs 1998;55(1):31-45
3. Fine MJ, Chowdhry T, Ketema A. Outpatient management of community-acquired pneumonia. Hosp Pract (Off Ed) 1998;33(6): 123-33
4. Woodhead M. Community-acquired pneumonia guidelines -an international comparison: a view from Europe. Chest 1998; 113(3 Suppl):183-7S
5. Marrie TJ. Community-acquired pneumonia: epidemiology, etiology, treatment. Infect Dis Clin North Am 1998;12(3):723-40
6. Marrie TJ. Epidemiology of mild pneumonia. Semin Respir Infect 1998;13(1):3-7
7. Fraser KL, Grossman RF. What new antibiotics to offer in the outpatient setting. Semin Respir Infect 1998;13(1):24-35
8. Bartlett JG, Breiman RF, Mandell LA, et al, for the Infectious Diseases Society of America. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998;26(4):811-38
9. Riquelme R, Torres A, el-Ebiary M, et al. Community-acquired pneumonia in the elderly: clinical and nutritional aspects. Am J Respir Crit Care Med 1997;156(6):1908-14
10. Janssens JP, Gauthey L, Herrmann F, et al. Community-acquired pneumonia in older patients. J Am Geriatr Soc 1996;44(5): 539-44
11. Reimer LG, Carroll KC. Role of the microbiology laboratory in the diagnosis of lower respiratory tract infections. Clin Infect Dis 1998;26(3):742-8
12. File TM Jr, Tan JS, Plouffe JP. Community-acquired pneumonia. What's needed for accurate diagnosis. Postgrad Med 1996;99(1): 95-107
13. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336(4):243-50
14. Cassiere HA, Fein AM. Duration and route of antibiotic therapy in community-acquired pneumonia: switch and step-down therapy. Semin Respir Infect 1998;13(1):36-42
15. MacDonald KS, Scriver SR, Skulnick M, et al. Community-acquired pneumonia: the future of the microbiology laboratory: focused diagnosis or syndromic management? Semin Respir Infect 1994;9(3):180-8
16. Laurichesse H, Robin F, Gerbaud L, et al, for the Study Group of General Practitioners. Empirical therapy for nonhospitalized patients with community-acquired pneumonia. Eur Respir J 1998;11(1):73-8
17. Niederman MS. Empirical therapy of community-acquired pneumonia. Semin Respir Infect 1994;9(3):192-8
18. Syrjala H, Broas M, Suramo I, et al. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 1998;27(2):358-63
19. Tanaka N, Matsumoto T, Kuramitsu T, et al. High resolution CT findings in community-acquired pneumonia. J Comput Assist Tomogr 1996;20(4):600-8
20. Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. Infect Agents Dis 1994;3(5):266-73
21. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998;2(1):10-5
22. Murray BE. Antibiotic resistance. Adv Intern Med 1997; 42:339-67
23. Hendley JO. The problem of antibiotic resistance. Va Med Q 1997;124(2):96-8
24. Hawkey PM. The origins and molecular basis of antibiotic resistance. BMJ 1998;317(7159):657-60
25. Goossens H, Sprenger MJ. Community acquired infections and bacterial resistance. BMJ 1998;317(7159):654-7
26. Doern GV. Trovafloxacin: a new extended-spectrum fluoroquinolone with real potential for the management of infections due to Streptococcus pneumoniae. Formulary 1998;33(Suppl 3):21-6S
27. Monnet DL, Archibald LK, Phillips L, et al. Antimicrobial use and resistance in eight US hospitals: complexities of analysis and modeling. Intensive Care Antimicrobial Resistance Epidemiology Project and National Nosocomial Infections Surveillance System Hospitals. Infect Control Hosp Epidemiol 1998;19(6):388-94
28. Plouffe JF, Breiman RF, Facklam RR, for the Franklin County Pneumonia Study Group. Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention. JAMA 1996; 275(3):194-8
29. Tremolieres F, de Kock F, Pluck N, et al. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis 1998;17(6):447-53
30. Thornsberry C, Ogilvie P, Kahn J, et al, for the Laboratory Investigator Group. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn Microbiol Infect Dis 1997;29(4):249-57
31. Thornsberry C, Burton PH, Vanderhoof BH. Activity of penicillin and three third-generation cephalosporins against US isolates of Streptococcus pneumoniae: a 1995 surveillance study. Diagn Microbiol Infect Dis 1996;25(2):89-95
32. Joshi N, Miller DQ. Doxycycline revisited. Arch Intern Med 1997;157(13):1421-8
33. Gruneberg RN, Felmingham D. Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. Diagn Microbiol Infect Dis 1996;25(4):169-81
34. Pankuch GA, Visalli MA, Jacobs MR, et al. Susceptibilities of penicillin-and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother 1998;42(3):624-30
35. Craig WA. Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J 1998;77(6 Suppl):7-11
36. Schentag JJ, Nix DE, Forrest A, et al. AUIC - the universal parameter within the constraint of a reasonable dosing interval. Ann Pharmacother 1996;30(9):1029-31
37. Dalla Costa T, Derendorf H. AUIC - a general target for the optimization of dosing regimens of antibiotics? Ann Pharmacother 1996;30(9):1024-8
38. Bergeron MG, Ouellette M. Preventing antibiotic resistance through rapid genotypic identification of bacteria and of their antibiotic resistance genes in the clinical microbiology laboratory. J Clin Microbiol 1998;36(8):2169-72
39. Bergeron MG, Ouellette M. Preventing antibiotic resistance using rapid DNA-based diagnostic tests. Infect Control Hosp Epidemiol 1998;19(8):560-4
40. Hancock RE. The role of fundamental research and biotechnology in finding solutions to the global problem of antibiotic resistance. Clin Infect Dis 1997;24(Suppl 1):148-50S
41. Belongia EA, Schwartz B. Strategies for promoting judicious use of antibiotics by doctors and patients. BMJ 1998;317(7159): 668-71
42. Williams RJ, Ryan MJ. Surveillance of antimicrobial resistance - an international perspective. BMJ 1998;317(7159):651
43. Struelens MJ. The epidemiology of antimicrobial resistance in hospital acquired infections: problems and possible solutions. BMJ 1998;317(7159):652-4
44. Huovinen P, Cars O. Control of antimicrobial resistance: time for action. The essentials of control are already well known. BMJ 1998;317(7159):613-4
45. Livermore DM, Macgowan AP, Wale MC. Surveillance of antimicrobial resistance: centralised surveys to validate routine data offer a practical approach. BMJ 1998;317(7159):614-5
46. Ortqvist A, Hedlund J, Burman LA, et al, for the Swedish Pneumococcal Vaccination Study Group. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998; 351(9100):399-403
47. Koivula I, Sten M, Leinonen M, et al. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997;103(4):281-90
48. Arunabh, Niederman MS. Strategies for prevention of community-acquired pneumonia. Semin Respir Infect 1998;13(1):68-78
49. Brown PD, Lerner SA. Community-acquired pneumonia. Lancet 1998;352(9136):1295-302
50. Low DE. Resistance issues and treatment implications: pneumococcus, Staphylococcus aureus, and gram-negative rods. Infect Dis Clin North Am 1998;12(3):613-30
51. Auble TE, Yealy DM, Fine MJ. Assessing prognosis and selecting an initial site of care for adults with community-acquired pneumonia. Infect Dis Clin North Am 1998;12(3):741-59